By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nippon Kayaku Co., Ltd. 

11-2, Fujimi 1 chome

Chiyoda-ku  Tokyo  102-8172  Japan
Phone: 81-3-3237-5046 Fax:



Company News
Debiopharm Has Won Its Patent Infringement Suit For Elplat Against Nippon Kayaku Co., Ltd. 3/4/2016 6:30:25 AM
Eiger Biopharma Announces License Agreement With Nippon Kayaku Co., Ltd. To Develop Bestatin (ubenimex) For Inflammatory Diseases Involving LTB4 11/9/2015 7:22:26 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Initiation of a Required Phase 1 Study of Apaziquone in Japan by Nippon Kayaku Co., Ltd. 1/6/2011 9:42:34 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Receipt of $16 Million from Asian Partners, Such As Nippon Kayaku Co., Ltd. Related to Apaziquone Collaboration Agreements Announced in November 2009 1/29/2010 7:55:39 AM
Spectrum Pharmaceuticals, Inc. (SPPI) and Nippon Kayaku Co., Ltd. Enter Collaboration Agreement for Apaziquone in Asian Territories 11/10/2009 9:17:16 AM
BioSphere Medical, Inc. (BSMD) Enters into Exclusive Distribution Agreement with Nippon Kayaku Co., Ltd. for Japanese Market 4/16/2009 8:21:00 AM
Toyota Tsusho America, Inc. and Nippon Kayaku Co., Ltd. Announce the Formation of GlycoMark, a Joint Venture to Develop and Commercialize Novel Biomarkers for Diabetes 7/17/2008 7:37:51 AM
NeoPharm (NEOL) Says Japan's Nippon Kayaku Co., Ltd. Terminates License Agreement 9/14/2007 8:08:14 AM
Shionogi & Co., Ltd. And Nippon Kayaku Co., Ltd. To Release Cetrotide In Japan 9/21/2006 3:44:33 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Announces A License And Collaboration Agreement For Ozarelix With Nippon Kayaku Co., Ltd. For The Japanese Market 8/4/2006 11:06:54 AM